Suppr超能文献

14个国家孕期锂的使用情况

Lithium Use During Pregnancy in 14 Countries.

作者信息

Wittström Felix, Cesta Carolyn E, Bateman Brian T, Bendix Marie, Bliddal Mette, Chan Adrienne Y L, Cho Yongtai, Choi Eun-Young, Cohen Jacqueline M, Donald Sarah, Gissler Mika, Havard Alys, Hernandez-Diaz Sonia, Huybrechts Krista F, Kollhorst Bianca, Lai Edward Chia-Cheng, Leinonen Maarit K, Li Brian M H, Man Kenneth K C, Ng Vanessa W S, Parkin Lianne, Pazzagli Laura, Rasmussen Lotte, Rotem Ran S, Schink Tania, Shin Ju-Young, Tran Duong T, Wong Ian C K, Zoega Helga, Reutfors Johan

机构信息

Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California.

出版信息

JAMA Netw Open. 2024 Dec 2;7(12):e2451117. doi: 10.1001/jamanetworkopen.2024.51117.

Abstract

IMPORTANCE

In pregnancy, the benefits of lithium treatment for relapse prevention in psychiatric conditions must be weighed against potential teratogenic effects. Currently, there is a paucity of information on how and when lithium is used by pregnant women.

OBJECTIVE

To examine lithium use in the perinatal period.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study used individual-level data of pregnancies from January 1, 2000, to December 31, 2021, in Australia, Denmark, Finland, Germany, Hong Kong, Iceland, Israel, New Zealand, Norway, South Korea, Sweden, Taiwan, the UK, and 2 cohorts in the US. Analyses were performed from September 1 to November 30, 2023.

EXPOSURES

The prevalence of lithium use as the proportion of pregnancies with at least 1 prescription fill or prescription within 3 months before pregnancy until childbirth was estimated using a common protocol. Lithium use during pregnancy by trimester and in the 3 months before and after pregnancy was examined.

MAIN OUTCOMES AND MEASURES

Comparison of prevalence between the first and last 3-year periods of available data.

RESULTS

Among 21 659 454 pregnancies from all collaborating sites, the prevalence of lithium use ranged from 0.07 per 1000 pregnancies in Hong Kong to 1.56 per 1000 in the US publicly insured population. Lithium use increased per 1000 pregnancies in 10 populations (Australia [0.60 to 0.74], Denmark [0.09 to 0.51], Finland [0.10 to 0.29], Iceland [0.24 to 0.99], Israel [0.25 to 0.37], Norway [0.24 to 0.47], South Korea [0.30 to 0.44], Sweden [0.42 to 1.07], the UK [0.07 to 0.10], and Taiwan [0.15 to 0.19]), remained stable in 4 populations (Germany [0.17 to 0.16], Hong Kong [0.06 to 0.06], and the publicly [1.50 to 1.34] and commercially [0.38 to 0.36] insured US populations), and decreased in 1 population (New Zealand [0.54 to 0.39]). Use of lithium decreased with each trimester of pregnancy, while prevalence of postpartum use was similar to prepregnancy levels. The proportion of lithium use in the second trimester compared with the prepregnancy period ranged from 2% in South Korea to 80% in Denmark.

CONCLUSIONS AND RELEVANCE

Prevalence of lithium use in pregnant women over the past 2 decades varied markedly between populations. Patterns of use before, during, and after pregnancy suggest that many women discontinued lithium use during pregnancy and reinitiated treatment after childbirth, with large variations between countries. These findings underscore the need for internationally harmonized guidelines, specifically for psychiatric conditions among pregnant women that may benefit from lithium treatment.

摘要

重要性

在孕期,必须权衡锂盐治疗预防精神疾病复发的益处与潜在致畸作用。目前,关于孕妇如何以及何时使用锂盐的信息匮乏。

目的

研究围产期锂盐的使用情况。

设计、设置和参与者:这项队列研究使用了2000年1月1日至2021年12月31日在澳大利亚、丹麦、芬兰、德国、中国香港、冰岛、以色列、新西兰、挪威、韩国、瑞典、中国台湾、英国以及美国的2个队列中的妊娠个体水平数据。分析于2023年9月1日至11月30日进行。

暴露因素

采用通用方案估计锂盐使用的患病率,即妊娠前3个月至分娩期间至少有1次处方配药或处方的妊娠比例。研究了孕期各 trimester以及妊娠前3个月和后3个月的锂盐使用情况。

主要结局和测量指标

比较可用数据的第一个和最后一个3年期间的患病率。

结果

在所有合作地点的21659454例妊娠中,锂盐使用的患病率从中国香港每1000例妊娠中的0.07例到美国公共保险人群中的每1000例1.56例不等。10个地区每1000例妊娠中的锂盐使用量增加(澳大利亚[从0.60增至0.74]、丹麦[从0.09增至0.51]、芬兰[从0.10增至0.29]、冰岛[从0.24增至0.99]、以色列[从0.25增至0.37]、挪威[从0.24增至0.47]、韩国[从0.30增至0.44]、瑞典[从0.42增至1.07]、英国[从0.07增至0.10]、中国台湾[从0.15增至0.19]),4个地区保持稳定(德国[从0.17降至0.16]、中国香港[从0.06降至0.06]、美国公共[从1.50降至1.34]和商业[从0.38降至0.36]保险人群),1个地区下降(新西兰[从0.54降至0.39])。随着孕期进展,锂盐使用量减少,而产后使用患病率与妊娠前水平相似。妊娠中期与妊娠前期间锂盐使用的比例在韩国为2%,在丹麦为80%。

结论及相关性

在过去20年中,不同人群中孕妇锂盐使用的患病率差异显著。妊娠前、期间和后的使用模式表明,许多女性在孕期停用锂盐,产后重新开始治疗,各国之间存在很大差异。这些发现强调了制定国际统一指南的必要性,特别是针对可能从锂盐治疗中获益的孕妇精神疾病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验